Floatz logo

Edrecolomab

Signet Ring Adenocarcinoma of the Colon

National Cancer Institute (NCI)monoclonal_antibodyPhase 3Dormant
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Signet Ring Adenocarcinoma of the Colon cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
University of Southern California
Phase 3BBB
Calcium folinate pentahydrate
University of Southern California
Phase 3BB
Eloxatin
John Hays
Phase 3BB
Irinotecan
Fox Chase Cancer Center
Phase 3BB
Cetuximab
National Cancer Institute (NCI)
Phase 2B

View all 22 →

Same molecule, other indications

Edrecolomab is also rated in:

colon mucinous adenocarcinomaDormant
B
Indicative ·
61 / 100
View asset →
colon carcinomaDormant
B
Indicative ·
61 / 100
View asset →
colorectal cancerDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →